E company news, Xinshida (002527) issued an announcement on the abnormal fluctuation of stock trading on the evening of February 18, the company's current operating conditions are normal, and there have been no major changes in the internal and external business environment.

Editor: Zhou Yingtong

WeChat, QQ Space, QQ Weibo

More related articlesBaili Tianheng has been approved for phase II/III clinical trial of a neoadjuvant therapy drug for breast cancer, and the population of breast cancer patients in China is large, and new breakthroughs have been added to related innovative drugs. On the evening of February 18, Baili Tianheng (688506) announced that it had recently received the "Drug Clinical Trial Approval Notice" officially approved and issued by the State Drug Administration-... Securities Times E Company Pan Yurong 02-18 18:23Vanke will complete the third public debt repayment Pre-REITs are in the next cityVanke is making every effort to promote debt repayment in an orderly manner, and on February 18, the company announced two positive news at the same time. On the one hand, Vanke announced that it will repay its third public bond of the year as scheduled. On the other hand, Vanke announced the establishment of a new Pre-REIT fund with CITIC Goldstone, Xinhua Insurance, Dajia Insurance, etc. Securities Times E Company Zhang Yifan 02-18 18:23